HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ryding, J. Articles by Dillner, J. Search for Related Content PubMed PubMed Citation Articles by Ryding, J. Articles by Dillner, J. Agricola Articles by Ryding, J. Articles by Dillner, J.

Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles

¹ Department of Medical Microbiology, Malmö University Hospital, Lund University, UMAS, S-205 02 Malmö, Sweden
² Active Biotech Research AB, Lund, Sweden

Correspondence
J. Dillner
joakim.dillner{at}med.lu.se

Human papillomavirus type 16 (HPV-16) is a major cause of human cancer. Effective prophylactic vaccines are based on type-specific neutralizing antibodies. A major neutralizing epitope has been defined by the monoclonal antibody H16.V5. To investigate the importance of this epitope for overall immunogenicity of HPV-16, HPV-16 virus-like particles devoid of the H16.V5 epitope were engineered by site-directed mutagenesis of ten non-conserved, surface-exposed residues. Removal of the H16.V5-defined epitope had only a marginal effect on antigenic reactivity with antibodies in sera from infected subjects, but affected immunogenicity in experimental immunization of mice, with reduced induction of both antibody responses and CTL responses.

This article has been cited by other articles:

				N. Thones, A. Herreiner, L. Schadlich, K. Piuko, and M. Muller A Direct Comparison of Human Papillomavirus Type 16 L1 Particles Reveals a Lower Immunogenicity of Capsomeres than Viruslike Particles with Respect to the Induced Antibody Response J. Virol., June 1, 2008; 82(11): 5472 - 5485. [Abstract] [Full Text] [PDF]